<li>abobotulinumtoxina<p>abobotulinumtoxina and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>aclidinium<p>ipratropium and aclidinium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>amantadine<p>ipratropium, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.</p></li><li>ambenonium<p>ambenonium increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>amisulpride<p>ipratropium decreases levels of amisulpride by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of amisulpride by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>amisulpride increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>amitriptyline<p>ipratropium and amitriptyline both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>amoxapine<p>ipratropium and amoxapine both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>anticholinergic/sedative combos<p>anticholinergic/sedative combos and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>aripiprazole<p>ipratropium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>atracurium<p>atracurium and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>atropine<p>atropine and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>atropine iv/im<p>atropine iv/im and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>belladonna alkaloids<p>belladonna alkaloids and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>belladonna and opium<p>ipratropium and belladonna and opium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>benperidol<p>ipratropium decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>benperidol increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>benztropine<p>benztropine and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. </p></li><li>bethanechol<p>bethanechol increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>buclizine<p>buclizine and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>carbachol<p>carbachol increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>cevimeline<p>cevimeline increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>chlorpromazine<p>ipratropium decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>chlorpromazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>cisatracurium<p>cisatracurium and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>clomipramine<p>ipratropium and clomipramine both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>clozapine<p>ipratropium decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>clozapine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>cyclizine<p>cyclizine and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>cyclobenzaprine<p>cyclobenzaprine and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>darifenacin<p>darifenacin and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>desipramine<p>ipratropium and desipramine both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>dicyclomine<p>dicyclomine and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>diphenhydramine<p>diphenhydramine and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>distigmine<p>distigmine increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>donepezil<p>donepezil increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dosulepin<p>ipratropium and dosulepin both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>doxepin<p>ipratropium and doxepin both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>droperidol<p>ipratropium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>droperidol increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>echothiophate iodide<p>echothiophate iodide increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>edrophonium<p>edrophonium increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>fesoterodine<p>fesoterodine and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>flavoxate<p>flavoxate and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>fluphenazine<p>ipratropium decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>fluphenazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>galantamine<p>galantamine increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>glycopyrrolate<p>glycopyrrolate and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>glycopyrrolate inhaled<p>glycopyrrolate inhaled and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>haloperidol<p>ipratropium decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>haloperidol increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>henbane<p>henbane and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>homatropine<p>homatropine and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>huperzine a<p>huperzine a increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>hyoscyamine<p>hyoscyamine and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>hyoscyamine spray<p>hyoscyamine spray and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>iloperidone<p>ipratropium decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>iloperidone increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>imipramine<p>ipratropium and imipramine both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>incobotulinumtoxina<p>incobotulinumtoxina and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>lofepramine<p>ipratropium and lofepramine both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>loxapine<p>ipratropium decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>loxapine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>loxapine inhaled<p>loxapine inhaled increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.<span><br><br></span>ipratropium decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>maprotiline<p>ipratropium and maprotiline both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>meclizine<p>ipratropium and meclizine both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>mepenzolate<p>ipratropium and mepenzolate both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>methscopolamine<p>ipratropium and methscopolamine both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>mianserin<p>ipratropium and mianserin both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>neostigmine<p>neostigmine increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>nortriptyline<p>ipratropium and nortriptyline both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>olanzapine<p>ipratropium decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>olanzapine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>onabotulinumtoxina<p>onabotulinumtoxina and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>orphenadrine<p>ipratropium and orphenadrine both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>oxybutynin<p>ipratropium and oxybutynin both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>oxybutynin topical<p>ipratropium and oxybutynin topical both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>oxybutynin transdermal<p>ipratropium and oxybutynin transdermal both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>paliperidone<p>ipratropium decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>paliperidone increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>pancuronium<p>ipratropium and pancuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>perphenazine<p>ipratropium decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>perphenazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>physostigmine<p>physostigmine increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>pilocarpine<p>pilocarpine increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>pilocarpine ophthalmic<p>pilocarpine ophthalmic increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>pimozide<p>ipratropium decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>pimozide increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>pralidoxime<p>ipratropium and pralidoxime both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>prochlorperazine<p>ipratropium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>prochlorperazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>promethazine<p>ipratropium decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>promethazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>propantheline<p>ipratropium and propantheline both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>protriptyline<p>ipratropium and protriptyline both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>pyridostigmine<p>pyridostigmine increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>quetiapine<p>ipratropium decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>quetiapine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>rapacuronium<p>ipratropium and rapacuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>rimabotulinumtoxinb<p>rimabotulinumtoxinb and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>risperidone<p>risperidone increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>rocuronium<p>ipratropium and rocuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>scopolamine<p>ipratropium and scopolamine both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>sertindole<p>ipratropium decreases levels of sertindole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of sertindole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>sertindole increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>solifenacin<p>ipratropium and solifenacin both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>succinylcholine<p>succinylcholine increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>sulpiride<p>ipratropium decreases levels of sulpiride by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of sulpiride by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>sulpiride increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>tacrine<p>tacrine increases and ipratropium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>thioridazine<p>ipratropium decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>thioridazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>thiothixene<p>ipratropium decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>thiothixene increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>tiotropium<p>ipratropium and tiotropium both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>tolterodine<p>ipratropium and tolterodine both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>trazodone<p>ipratropium and trazodone both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>trifluoperazine<p>ipratropium decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>trifluoperazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>trihexyphenidyl<p>ipratropium and trihexyphenidyl both decrease  cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.</p></li><li>trimipramine<p>ipratropium and trimipramine both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>trospium chloride<p>ipratropium and trospium chloride both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>tubocurarine<p>ipratropium and tubocurarine both decrease  cholinergic effects/transmission. Use Caution/Monitor.</p></li><li>umeclidinium bromide<p>umeclidinium bromide and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor. If possible, avoid coadministration of additional anticholinergic agents </p></li><li>umeclidinium bromide/vilanterol inhaled<p>ipratropium, umeclidinium bromide/vilanterol inhaled.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. If possible, avoid coadministration of additional anticholinergic agents.</p></li><li>vecuronium<p>ipratropium and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium,  interaction unlikely at regularly recommended dosages.</p></li><li>ziprasidone<p>ipratropium decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>ziprasidone increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>zotepine<p>ipratropium decreases levels of zotepine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of zotepine by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>zotepine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li>